Characterisation and development of adjuvants for new generation veterinary and human vaccines. Vaccination is the most successful and cost-effective means of combating infectious diseases in both veterinary and human medicine. This project will increase our understanding of how vaccines work and will help the development of new vaccines against infections in both animals and man. The results of these studies will also increase the competitiveness of Australian scientists in the field of vaccine ....Characterisation and development of adjuvants for new generation veterinary and human vaccines. Vaccination is the most successful and cost-effective means of combating infectious diseases in both veterinary and human medicine. This project will increase our understanding of how vaccines work and will help the development of new vaccines against infections in both animals and man. The results of these studies will also increase the competitiveness of Australian scientists in the field of vaccine research and development.Read moreRead less
Development of an effective vaccine for chlamydial infection: optimisation of a non-toxic cholera toxin-based adjuvant to generate a protective mucosal response. Chlamydial genital infections are the most common sexually transmitted infection in Australia and the world and impose a major health burden on the community. Chlamydial infections are also associated with cardiovascular disease, Australia's biggest killer and asthma, another condition that has increased significantly in prevalence in t ....Development of an effective vaccine for chlamydial infection: optimisation of a non-toxic cholera toxin-based adjuvant to generate a protective mucosal response. Chlamydial genital infections are the most common sexually transmitted infection in Australia and the world and impose a major health burden on the community. Chlamydial infections are also associated with cardiovascular disease, Australia's biggest killer and asthma, another condition that has increased significantly in prevalence in the past 10 years. This project will evaluate the effectiveness of a new adjuvant as a first step towards the development of a vaccine to target these important infections.Read moreRead less
Novel lipid-based adjuvants for induction of mucosal immunity. The project will determine if needle-free oral and transcutaneous immunisation using LipoVax, a novel lipid-based antigen delivery system developed by the industry partner, can protect mice against the mucosal pathogens Chlamydia and Helicobacter. We expect to show that this immunisation method can induce protective mucosal immunity against two of the most common infectious organisms affecting mankind. If successful this will allow u ....Novel lipid-based adjuvants for induction of mucosal immunity. The project will determine if needle-free oral and transcutaneous immunisation using LipoVax, a novel lipid-based antigen delivery system developed by the industry partner, can protect mice against the mucosal pathogens Chlamydia and Helicobacter. We expect to show that this immunisation method can induce protective mucosal immunity against two of the most common infectious organisms affecting mankind. If successful this will allow us to develop LipoVax as a new platform technology that can be applied to the development of human vaccines, veterinary vaccines, vaccines for companion animals and vaccines to target infections in feral animals and native wildlife population populations.Read moreRead less
Foreign DNA is a danger signal for mammalian cells. This project investigates how cells normally respond to foreign DNA, and is relevant to understanding how the body fights infections, particularly by viruses. The results will help us to design more effective treatments for infectious disease. Studying responses to DNA will also promote the design of new treatments for the autoimmune disease lupus, and help improve technologies or treatments where DNA is introduced into cells or tissues. This ....Foreign DNA is a danger signal for mammalian cells. This project investigates how cells normally respond to foreign DNA, and is relevant to understanding how the body fights infections, particularly by viruses. The results will help us to design more effective treatments for infectious disease. Studying responses to DNA will also promote the design of new treatments for the autoimmune disease lupus, and help improve technologies or treatments where DNA is introduced into cells or tissues. This includes gene therapy, new strategies for vaccination, and the production of proteins as drugs by biotechnology. The project will promote National Research Priorities in the areas of preventative healthcare, ageing well ageing productively, breakthrough science and new technologies.Read moreRead less
Application of in vivo electroporation to DNA immunisation. The in vivo delivery of plasmid DNA induces immune responses to the encoded protein vaccine. In large animals including humans, DNA vaccination needs to be further improved before becoming a commercial reality, at least partially due to the very low levels of expression in vivo. In vivo electroporation has proven to be an effective way to enhance the level of protein expression and increase DNA vaccine efficacy. We combine enhanced in ....Application of in vivo electroporation to DNA immunisation. The in vivo delivery of plasmid DNA induces immune responses to the encoded protein vaccine. In large animals including humans, DNA vaccination needs to be further improved before becoming a commercial reality, at least partially due to the very low levels of expression in vivo. In vivo electroporation has proven to be an effective way to enhance the level of protein expression and increase DNA vaccine efficacy. We combine enhanced in vivo expression using electroporation with the co-delivery of plasmids encoding cytokines to enhance and modulate DNA vaccine in sheep. We will apply our findings to bovine viral diarrhoea virus (BVDV), both as an animal model for humans and as an economically important diseases of livestock.Read moreRead less
Improving immune response to vaccines by selective targeting of epithelial regions with the Nanopatch. Vaccination protects us from infections like measles and flu. In principle, it could protect us from all diseases, even from skin cancer and arthritis. In practice, however, vaccines to diseases like cancer have largely proved ineffective. One problem is that we don't really understand how the body's immune system responds to vaccination. Our aim, therefore, is to investigate changes in the imm ....Improving immune response to vaccines by selective targeting of epithelial regions with the Nanopatch. Vaccination protects us from infections like measles and flu. In principle, it could protect us from all diseases, even from skin cancer and arthritis. In practice, however, vaccines to diseases like cancer have largely proved ineffective. One problem is that we don't really understand how the body's immune system responds to vaccination. Our aim, therefore, is to investigate changes in the immune system when a vaccine enters the skin, as might happen by injection. Experimenting with laboratory mice and a special vaccine-injecting Nanopatch that is attached to each mouse's ear, we are starting to understand how a vaccine affects the immune cells in the skin. In the future we plan to apply this knowledge to improve vaccination in people.Read moreRead less
Optimising the body's immune response with a Nanopatch that delivers biomolecules to the skin. The team is developing a new improved way to vaccinate against deadly infectious diseases such as influenza and malaria. They believe their Nanopatch technology will boost the power of seasonal influenza vaccination and could even solve vaccine shortages in an influenza pandemic. This is because the Nanopatch needs much less vaccine per person than a conventional syringe. They also predict that vaccine ....Optimising the body's immune response with a Nanopatch that delivers biomolecules to the skin. The team is developing a new improved way to vaccinate against deadly infectious diseases such as influenza and malaria. They believe their Nanopatch technology will boost the power of seasonal influenza vaccination and could even solve vaccine shortages in an influenza pandemic. This is because the Nanopatch needs much less vaccine per person than a conventional syringe. They also predict that vaccines delivered with a Nanopatch will require less refrigeration than conventional vaccines and can be safely administered by individuals without medical training, making the benefits of vaccination accessible to more people more cheaply, even in remote areas.Read moreRead less
Micro-nanoprojection patches for minimally-invasive and targeted delivery of genes and drugs to skin cells: from concept to technology platform. This project will address key science questions on the recently patented micro-nanoprojections patch, establishing it in Australia as a world leading technology in the rapidly growing and important field of gene and drug delivery. Unique internationally-competitive science outcoumes and research training will be generated at the interfaces between bioen ....Micro-nanoprojection patches for minimally-invasive and targeted delivery of genes and drugs to skin cells: from concept to technology platform. This project will address key science questions on the recently patented micro-nanoprojections patch, establishing it in Australia as a world leading technology in the rapidly growing and important field of gene and drug delivery. Unique internationally-competitive science outcoumes and research training will be generated at the interfaces between bioengineering, nanotechnology, pharmaceutical science and immunology. Ultimately, the project will allow improved treatment of major diseases (e.g. vaccination and immunotherapy of asthma). Achieving these health benefits by commercial pathways is expected to benefit the Australian community and emerging Biotechnology industry-creating highly valued career opportunities for Australians.Read moreRead less